tiprankstipranks
Supernus Pharmaceuticals (SUPN)
NASDAQ:SUPN
US Market
SUPN
Supernus Pharmaceuticals
RESEARCH TOOLSreports
Want to see SUPN full AI Analyst Report?

Supernus Pharmaceuticals (SUPN) Stock Forecast & Price Target

532 Followers
See the Price Targets and Ratings of:

SUPN Analyst Ratings

Strong Buy
6Ratings
Strong Buy
5 Buy
1 Hold
0 Sell
Based on 6 analysts giving stock ratings to
Supernus
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

SUPN Stock 12 Month Forecast

Average Price Target

$63.17
▲(22.92% Upside)
Based on 6 Wall Street analysts offering 12 month price targets for Supernus Pharmaceuticals in the last 3 months. The average price target is $63.17 with a high forecast of $66.00 and a low forecast of $55.00. The average price target represents a 22.92% change from the last price of $51.39.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"30":"$30","67":"$67","39.25":"$39.3","48.5":"$48.5","57.75":"$57.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":66,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$66.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":63.166666666666664,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$63.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":55,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$55.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[30,39.25,48.5,57.75,67],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,47.85,49.246153846153845,50.642307692307696,52.03846153846154,53.434615384615384,54.830769230769235,56.22692307692308,57.62307692307692,59.019230769230774,60.41538461538462,61.81153846153846,63.20769230769231,64.60384615384615,{"y":66,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,47.85,49.02820512820513,50.20641025641026,51.38461538461539,52.562820512820515,53.741025641025644,54.91923076923077,56.0974358974359,57.27564102564102,58.45384615384616,59.63205128205128,60.81025641025641,61.988461538461536,{"y":63.166666666666664,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,47.85,48.4,48.95,49.5,50.050000000000004,50.6,51.15,51.7,52.25,52.8,53.35,53.9,54.45,{"y":55,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":32.45,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.91,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.82,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.505,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.54,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.04,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.13,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.7,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.7,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.78,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.09,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.44,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.85,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$66.00Average Price Target$63.17Lowest Price Target$55.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Stifel Nicolaus Analyst forecast on SUPN
Annabel Samimy
Stifel Nicolaus
Stifel Nicolaus
$55
Hold
7.02%
Upside
Reiterated
05/06/26
Stifel Nicolaus Reaffirms Their Hold Rating on Supernus Pharmaceuticals (SUPN)
Piper Sandler Analyst forecast on SUPN
David Amsellem
Piper Sandler
Piper Sandler
$66
Buy
28.43%
Upside
Reiterated
05/06/26
Piper Sandler Reaffirms Their Buy Rating on Supernus Pharmaceuticals (SUPN)
TD Cowen Analyst forecast on SUPN
Stacy Ku
TD Cowen
TD Cowen
$65
Buy
26.48%
Upside
Reiterated
05/05/26
SUPN: Buy Rating Reiterated as Strong Growth Supports Unchanged $65 Price Target
Jefferies Analyst forecast on SUPN
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$60→$65
Buy
26.48%
Upside
Reiterated
03/24/26
Supernus Pharmaceuticals (SUPN) Gets a Buy from Jefferies
Cantor Fitzgerald Analyst forecast on SUPN
Kristen Kluska
Cantor Fitzgerald
Cantor Fitzgerald
$63
Buy
22.59%
Upside
Reiterated
02/24/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Oxford BioMedica (Other OTC: OXBDF), Valneva (NASDAQ: VALN) and Supernus Pharmaceuticals (NASDAQ: SUPN)
Bank of America Securities Analyst forecast on SUPN
Pavan Patel
Bank of America Securities
Bank of America Securities
$65
Buy
26.48%
Upside
Reiterated
02/24/26
Buy Rating Backed by Reaccelerating Onapgo Demand, Sage Integration Upside, and Attractive CNS-Driven Valuation
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Stifel Nicolaus Analyst forecast on SUPN
Annabel Samimy
Stifel Nicolaus
Stifel Nicolaus
$55
Hold
7.02%
Upside
Reiterated
05/06/26
Stifel Nicolaus Reaffirms Their Hold Rating on Supernus Pharmaceuticals (SUPN)
Piper Sandler Analyst forecast on SUPN
David Amsellem
Piper Sandler
Piper Sandler
$66
Buy
28.43%
Upside
Reiterated
05/06/26
Piper Sandler Reaffirms Their Buy Rating on Supernus Pharmaceuticals (SUPN)
TD Cowen Analyst forecast on SUPN
Stacy Ku
TD Cowen
TD Cowen
$65
Buy
26.48%
Upside
Reiterated
05/05/26
SUPN: Buy Rating Reiterated as Strong Growth Supports Unchanged $65 Price Target
Jefferies Analyst forecast on SUPN
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$60→$65
Buy
26.48%
Upside
Reiterated
03/24/26
Supernus Pharmaceuticals (SUPN) Gets a Buy from Jefferies
Cantor Fitzgerald Analyst forecast on SUPN
Kristen Kluska
Cantor Fitzgerald
Cantor Fitzgerald
$63
Buy
22.59%
Upside
Reiterated
02/24/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Oxford BioMedica (Other OTC: OXBDF), Valneva (NASDAQ: VALN) and Supernus Pharmaceuticals (NASDAQ: SUPN)
Bank of America Securities Analyst forecast on SUPN
Pavan Patel
Bank of America Securities
Bank of America Securities
$65
Buy
26.48%
Upside
Reiterated
02/24/26
Buy Rating Backed by Reaccelerating Onapgo Demand, Sage Integration Upside, and Attractive CNS-Driven Valuation
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Supernus Pharmaceuticals

3 Months
xxx
Success Rate
11/18 ratings generated profit
61%
Average Return
+4.77%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 61.11% of your transactions generating a profit, with an average return of +4.77% per trade.
1 Year
Stacy KuTD Cowen
Success Rate
14/18 ratings generated profit
78%
Average Return
+23.49%
Copying Stacy Ku's trades and holding each position for 1 Year would result in 77.78% of your transactions generating a profit, with an average return of +23.49% per trade.
2 Years
xxx
Success Rate
21/25 ratings generated profit
84%
Average Return
+7.39%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 84.00% of your transactions generating a profit, with an average return of +7.39% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SUPN Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
0
0
0
0
0
Buy
11
12
11
9
6
Hold
2
2
1
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
13
14
12
10
7
In the current month, SUPN has received 6 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. SUPN average Analyst price target in the past 3 months is 63.17.
Each month's total comprises the sum of three months' worth of ratings.

SUPN Financial Forecast

SUPN Earnings Forecast

Next quarter’s earnings estimate for SUPN is $0.44 with a range of $0.15 to $0.65. The previous quarter’s EPS was $0.60. SUPN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year SUPN has Performed in-line its overall industry.
Next quarter’s earnings estimate for SUPN is $0.44 with a range of $0.15 to $0.65. The previous quarter’s EPS was $0.60. SUPN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year SUPN has Performed in-line its overall industry.

SUPN Sales Forecast

Next quarter’s sales forecast for SUPN is $205.88M with a range of $202.80M to $207.50M. The previous quarter’s sales results were $207.71M. SUPN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year SUPN has Performed in-line its overall industry.
Next quarter’s sales forecast for SUPN is $205.88M with a range of $202.80M to $207.50M. The previous quarter’s sales results were $207.71M. SUPN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year SUPN has Performed in-line its overall industry.

SUPN Stock Forecast FAQ

What is SUPN’s average 12-month price target, according to analysts?
Based on analyst ratings, Supernus Pharmaceuticals’s 12-month average price target is 63.17.
    What is SUPN’s upside potential, based on the analysts’ average price target?
    Supernus Pharmaceuticals has 22.92% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is SUPN a Buy, Sell or Hold?
          Supernus Pharmaceuticals has a consensus rating of Strong Buy which is based on 5 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Supernus Pharmaceuticals’s price target?
            The average price target for Supernus Pharmaceuticals is 63.17. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $66.00 ,the lowest forecast is $55.00. The average price target represents 22.92% Increase from the current price of $51.39.
              What do analysts say about Supernus Pharmaceuticals?
              Supernus Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
                How can I buy shares of SUPN?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.